# Coherus BioSciences, Inc. (CHRS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CHRS
## Company Profile
- Ticker: CHRS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Biologics, Generics, Oncology
## Stock Data
- Close: 1.07 USD
- Market cap: 234459848 USD
- Last updated: 2026-10-13
## Business Overview
### Immuno-Oncology Portfolio
Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.
### Casdozokitug
Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma. The program targets IL-27-mediated immune suppression and is being evaluated in a randomized Phase 2 trial.
### Tagmokitug
Tagmokitug is a CCR8-directed antibody designed to selectively deplete regulatory T cells in tumors. Combination studies with toripalimab span head and neck, upper gastrointestinal, esophageal and colorectal cancers.
## Why The Stock Is Moving

The latest monitored company update is “Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initial data from the first-line HCC Phase 2 study of casdozokitug around mid-2026.
- Initial Phase 1b tagmokitug combination data in second-line head and neck and upper gastrointestinal cancers in mid-2026.
- First tagmokitug combination data in esophageal squamous-cell carcinoma in the second half of 2026.
- Initial tagmokitug combination data in late-line colorectal cancer in the second half of 2026.

## Recent News
- 2026-10-14 20:30 EST — [Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-host-webcast-to-disclose-interim-tagmokitug-clinical-data-on-8710ec2c) — Source: Coherus BioSciences, Inc.
- 2026-09-23 13:30 EST — [Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets](https://biopharmsignal.com/news/CHRS/coherus-oncology-retains-oppenheimer-co-to-market-legacy-biosimilar-assets-70f5fce6) — Source: Coherus BioSciences, Inc.
- 2026-08-31 13:30 EST — [Coherus to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CHRS/coherus-to-participate-in-upcoming-investor-conferences-2fec3539) — Source: Coherus BioSciences, Inc.
- 2026-08-17 21:33 EST — [Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights](https://biopharmsignal.com/news/CHRS/coherus-oncology-announces-special-dividend-of-biosimilar-contingent-value-right-b0dca6eb) — Source: Coherus BioSciences, Inc.
- 2026-08-05 20:28 EST — [Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-second-quarter-2026-financial-results-and-provides-busi-6d46d16c) — Source: Coherus BioSciences, Inc.